earnings
confidence high
sentiment positive
materiality 0.75
Glaukos Q2 net sales $185.6M (+50% YoY); raises FY2026 guidance to $680-700M
GLAUKOS Corp
- Record net sales $185.6M, up 50% YoY; U.S. glaucoma sales $118.5M (+64%).
- GAAP net loss $18.4M ($0.31/sh); non-GAAP net loss $8.3M ($0.14/sh), improved from $19.7M loss a year ago.
- Gross margin 82% (non-GAAP 85%), up from 78% (83%) YoY.
- Raised 2026 net sales guidance to $680-700M from prior $620-635M.
- Cash $289.3M, no debt; cites iDose TR and Epioxa as growth drivers.